Cargando…

Clinical efficacy of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) in the initial treatment of advanced stage (stage III–IV) extranodal NK/T-cell lymphoma, and its correlation with Epstein-Barr virus

Objective: To evaluate the clinical efficacy and safety of the DDGP regimen in treating extranodal NK/T-cell lymphoma and investigate the correlation between Epstein-Barr virus (EBV)-DNA variation after treatment and the clinical efficacy of NK/T-cell lymphoma. Methods: Sixty-four patients with extr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Qian, Fan, Shanshan, Chang, Yu, Liu, Xiyang, Li, Wencai, Ma, Qianwen, Li, Yang, Wang, Yan, Zhang, Lei, Zhang, Mingzhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Clinical Trial Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497975/ https://www.ncbi.nlm.nih.gov/pubmed/31118779 http://dx.doi.org/10.2147/CMAR.S191929

Ejemplares similares

The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type
por: Zhang, Lei, et al.
Publicado: (2016)

Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149
por: Zhang, Lei, et al.
Publicado: (2016)

Combination of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in treatment of advanced extranodal NK/T-cell lymphoma
por: Fu, Ruiying, et al.
Publicado: (2023)

Pegaspargase, gemcitabine, dexamethasone, and cisplatin (P-GDP) combined chemotherapy is effective for newly diagnosed extranodal NK/T-cell lymphoma: a retrospective study
por: Liu, Tao, et al.
Publicado: (2018)

Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma
por: Wang, Jing-hua, et al.
Publicado: (2016)

S100A9 and ORM1 serve as predictors of therapeutic response and prognostic factors in advanced extranodal NK/T cell lymphoma patients treated with pegaspargase/gemcitabine
por: Zhou, Zhiyuan, et al.
Publicado: (2016)

P1238: EFFICACY ANALYSIS OF PEGASPARGASE, GEMCITABINE, OXALIPLATIN, DEXAMETHASONE COMBINED WITH TISLELIZUMAB IN FIRST-LINE TREATMENT OF PLASMA EBV-DNA POSITIVE EXTRANODAL NK/T CELL LYMPHOMA
por: Yuan, X., et al.
Publicado: (2022)

Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma
por: Wang, Jing-hua, et al.
Publicado: (2016)

DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T‐cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients
por: Wang, Xin, et al.
Publicado: (2020)

Gemcitabine, dexamethasone, and cisplatin (GDP) chemotherapy with sandwiched radiotherapy in the treatment of newly diagnosed stage IE/IIE extranodal natural killer/T‐cell lymphoma, nasal type
por: Tian, Shu, et al.
Publicado: (2019)

Combined use of DDGP and IMRT has a good effect on extranodal natural killer/T‐cell lymphoma, nasal type
por: Zheng, Yingjuan, et al.
Publicado: (2019)

A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type
por: Xu, Peng-Peng, et al.
Publicado: (2017)

Treatment of Children with Advanced-Stage Lymphoblastic Lymphoma with Pegaspargase
por: Yu-tong, Zhang, et al.
Publicado: (2014)

Development of Extranodal NK/T-cell Lymphoma Nasal Type in Cerebrum Following Epstein-Barr Virus-positive Uveitis
por: Imai, Ayano, et al.
Publicado: (2017)

Superiority of Epstein-Barr Virus DNA in the Plasma Over Whole Blood for Prognostication of Extranodal NK/T Cell Lymphoma
por: Ha, Joo Young, et al.
Publicado: (2020)

GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
por: Wang, Jing-jing, et al.
Publicado: (2016)

P1150: A PROSPECTIVE PHASE II CLINICAL TRIAL USING CHIDAMIDE, TISLELIZUMAB, AND PEGASPARGASE IN COMBINATION WITH RADIOTHERAPY AS FIRST-LINE TREATMENT IN STAGES I/II OF EXTRANODAL NK/T-CELL LYMPHOMA
por: Zhou, Hui, et al.
Publicado: (2023)

Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamide, cisplatin, and etoposide (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphoma
por: Zhang, Yao, et al.
Publicado: (2021)

Pegaspargase Combined with Concurrent Radiotherapy for Early‐Stage Extranodal Natural Killer/T‐Cell Lymphoma, Nasal Type: A Two‐Center Phase II Study
por: Wang, Hua, et al.
Publicado: (2020)

Etoposide, dexamethasone, and pegaspargase with sandwiched radiotherapy in early-stage natural killer/T-cell lymphoma: A randomized phase III study
por: Zhong, Huijuan, et al.
Publicado: (2023)

Circulating Low Absolute CD4(+) T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy
por: Zhang, Ya-Ping, et al.
Publicado: (2019)

Extranodal NK/T-Cell Lymphoma, Nasal Type: Genetic, Biologic, and Clinical Aspects with a Central Focus on Epstein–Barr Virus Relation
por: Takahara, Miki, et al.
Publicado: (2021)

Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial
por: Bassan, Renato, et al.
Publicado: (2023)

Concurrent IMRT and weekly cisplatin followed by GDP chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell lymphoma
por: Ke, Q-H, et al.
Publicado: (2014)

Epstein-Barr Virus Genome Deletions in Epstein-Barr Virus-Positive T/NK Cell Lymphoproliferative Diseases
por: Wongwiwat, Wiyada, et al.
Publicado: (2022)

Utility of baseline, interim and end-of-treatment (18)F-FDG PET/CT in extranodal natural killer/T-cell lymphoma patients treated with L-asparaginase/pegaspargase
por: Chang, Yu, et al.
Publicado: (2017)

Development of a Lyophilized Formulation of Pegaspargase and Comparability Versus Liquid Pegaspargase
por: Faschinger, Alexander M., et al.
Publicado: (2019)

Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma
por: Peng, Rou-Jun, et al.
Publicado: (2018)

One method to establish Epstein‐Barr virus‐associated NK/T cell lymphoma mouse models
por: Xue, Weili, et al.
Publicado: (2018)

Epstein–Barr virus-positive T/NK-cell lymphoproliferative disorders
por: Cai, Qingqing, et al.
Publicado: (2015)

Epstein-Barr Virus-Associated T and NK-Cell Lymphoproliferative Diseases
por: Kim, Wook Youn, et al.
Publicado: (2019)

Cost effectiveness of concurrent gemcitabine and cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in stages IIB–IVA cervical cancer
por: Rajan, Narayan, et al.
Publicado: (2014)

Extranodal NK/T cell lymphoma
por: Jeong, Seong Hyun
Publicado: (2020)

Extranodal T- and NK-cell lymphomas
por: de Leval, Laurence, et al.
Publicado: (2022)

Efficacy of pegaspargase, etoposide, methotrexate and dexamethasone in newly diagnosed advanced-stage extra-nodal natural killer/T-cell lymphoma with the analysis of the prognosis of whole blood EBV-DNA
por: Liang, J-H, et al.
Publicado: (2017)

Deciphering the role of Epstein-Barr virus in the pathogenesis of T and NK cell lymphoproliferations
por: Fox, Christopher P, et al.
Publicado: (2011)

NK Cell Influence on the Outcome of Primary Epstein–Barr Virus Infection
por: Chijioke, Obinna, et al.
Publicado: (2016)

Editorial: Epstein-Barr Virus-Associated T/NK-Cell Lymphoproliferative Diseases
por: Fujiwara, Shigeyoshi, et al.
Publicado: (2019)

Transcriptomic Abnormalities in Epstein Barr Virus Associated T/NK Lymphoproliferative Disorders
por: de Mel, Sanjay, et al.
Publicado: (2019)

The value of routine bone marrow examination in patients with extranodal NK/T‐cell lymphoma staged with PET/CT
por: Yang, Yong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jb9qk3m2l0mt2debo37bi6kuqr